A major new clinical trial is testing whether rapamycin, a drug widely hyped as a longevity solution, actually works safely in older adults at doses that matter. Researchers at UT San Antonio are launching a multi-phase study funded by the National Institute on Aging to move beyond speculation and establish evidence-based guidance for the drug's use in extending health span, the years people live in good health. Why Is Rapamycin Getting So Much Attention in Anti-Aging Circles? Rapamycin has become a darling of the longevity community, with wealthy individuals and biohackers experimenting with it based on promising laboratory research. The drug, originally developed as an immunosuppressant for organ transplant patients, has shown potential in animal studies to extend lifespan and improve various aging markers. However, there's a critical gap between what looks promising in the lab and what actually works safely in people. "Rapamycin is widely discussed in popular culture as a longevity drug. But there's a difference between something that is biologically plausible and something that has been rigorously tested in people," said Ellen Kraig, PhD, professor in the Department of Cell Systems and Anatomy at UT San Antonio. Ellen Kraig, PhD, Professor, Department of Cell Systems and Anatomy, UT San Antonio This distinction matters enormously. Popular culture often conflates theoretical potential with proven benefit, leaving people uncertain about whether they should pursue these treatments. What Exactly Will This Clinical Trial Measure? The randomized, placebo-controlled trial will include approximately 84 older adults between ages 65 and 90 and will evaluate both short-term and longer-term effects of rapamycin and everolimus, a related drug. The study is designed as a series of sub-studies, each addressing specific questions about how the drug works in the human body. The research team, led by Dean Kellogg Jr., MD, PhD, professor in the Department of Medicine, Division of Geriatrics, Gerontology and Palliative Medicine, emphasizes that this phase is about precision. "We're asking how much drug it actually takes to achieve a desired biological effect, not more than that," Kellogg explained. This approach contrasts sharply with the trial-and-error dosing many people attempt on their own. The study will examine several key areas: - Biological Markers: Researchers will measure how rapamycin affects cellular and molecular indicators of aging, such as inflammation levels and metabolic function. - Optimal Dosing: The trial will determine what dose produces meaningful biological effects without unnecessary side effects or risks. - Safety Profile: Long-term safety data in older adults will help identify who can safely use the drug and under what conditions. - Outcomes in Aging: The study will assess whether improvements in biological markers translate to real-world benefits in physical function and quality of life. How to Participate in This Groundbreaking Research - Age Range: You must be between 65 and 90 years old to qualify for the six-week clinical trial followed by a four-week follow-up period. - Health Status: Participants should be generally healthy, non-smokers who live independently and do not have diabetes or use glucose-lowering medications. - Contact Information: Interested individuals can email the research team or call (210) 450-3333 for more details about enrollment. The trial represents a significant shift in how the scientific community approaches longevity research. Rather than accepting anecdotal reports or small preliminary studies, researchers are demanding the same rigorous evidence standards applied to any other medical treatment. The UT San Antonio team includes multiple specialists working together to ensure comprehensive evaluation. Ellen Kraig and colleagues manage laboratory and logistical operations, while Brett Ginsburg, PhD, professor in the Department of Psychiatry and Behavioral Sciences, oversees the pharmacological aspects. Clinical management is handled by Dean Kellogg and Tiffany Cortes, MD, at the Sam and Ann Barshop Institute for Longevity and Aging Studies Research Clinic. This multi-disciplinary approach reflects the complexity of studying aging interventions. Aging affects multiple body systems simultaneously, so understanding rapamycin's effects requires expertise in cellular biology, geriatric medicine, psychiatry, and statistics. The involvement of Randy Strong, PhD, professor of pharmacology and associate director for translational research at the Barshop Institute, and Adam Salmon, PhD, professor of molecular medicine, adds additional scientific rigor to the project. The findings from this study are expected to inform future aging research and potential clinical applications, potentially reshaping how doctors approach anti-aging interventions. Rather than relying on hype or individual experimentation, clinicians will have evidence-based guidance about whether, when, and how to use rapamycin for healthy aging. For people interested in longevity science, this trial represents a crucial step toward separating fact from fiction in the rapidly expanding field of anti-aging medicine.
